Press release
Illumina and Henry Ford Health team up to study impact of comprehensive genomic testing for cardiovascular patients
Series of studies will focus on genetic drivers of cardiovascular disease, and how data can improve care, especially in underserved communities SAN DIEGO,
About this update from Illumina, Inc.
[{"type":"text","content":"Series of studies will focus on genetic drivers of cardiovascular disease, and how data can improve care, especially in underserved communities \nSAN DIEGO, April 11, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Henry Ford Health, a not-for-profit health care organization in the Detroit metro area, today announced the launch of a partnership to assess the impact of comprehensive genomic testing in cardiovascular disease. The first study under this new partnership, CardioSeq, launches today and will include 1500 patients receiving care from the Division of Cardiovascular Medicine at Henry Ford.\n\n \n \n \n \n \n \n\n \nThe Lisa and Christopher Jeffries Center for Precision Medicine and the Center for Individualized and Genomic Medicine Research at Henry Ford Health will conduct a series of implementation and clinical studies that will investigate the use of next-generation sequencing tests, including whole-genome sequencing (WGS), to assess their impact on clinical care. The studies will focus on cardiovascular disease, an area that imposes a substantial clinical and economic burden on the health care ecosystem, with a particular interest in diverse and underserved populations.\n\"This study is the first of several that will measure the impact of whole-genome sequencing in patients with cardiovascular disease,\" said Dr. David Lanfear, vice president of clinical and translational research at Henry Ford Health and the study's lead clinician. \"What we're initially most interested in is the rate of the change in medical management due to the genetic information, but eventually we will be looking at differences in cost and clinical outcomes as well.\"\nDr. Phil Febbo, chief medical officer of Illumina, added: \"We are honored to partner with Henry Ford Health to assess the potential benefits of integrating genomic testing within specialized care centers in the health care system. We share the belief that genomics should be integrated into standard of care across clinical indications as one of the key determinants of health. We intend for our partnership to demonstrate the benefits of such an approach for individual patients and the broader health care system, especially in underserved communities.\"\nCardiovascular disease is the leading cause of death global...